Arca
Skip to content
Tools
Tools

IL31RA: Interleukin-31 receptor subunit alpha

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Functions as a membrane-bound signal-transducing subunit of the IL31 receptor complex (heterodimer composed of OSMR and IL31RA) which binds IL31.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1
  • Type: Protein

Who Is On It, and How Far Along

Every drug ChEMBL records acting on IL31RA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody

Approved1

  • Nemolizumab

Phase 30

    Phase 20

      Phase 10

        The Landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionMechanismOpen trialsWarnings
        NemolizumabApprovedGalderma LaboratoriesAntibodyInhibitorInterleukin-31 receptor subunit alpha inhibitor15—

        Open Trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients ≥ 12yo With Dystrophic Epidermolysis BullosaNemolizumabPhase 2 / Phase 3Not yet recruitingCentre Hospitalier Universitaire de Nice2026-11-09
        ADBest TREAT RegistryNemolizumab—RecruitingUniversitätsklinikum Hamburg-Eppendorf2026-10-29
        Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic PruritusNemolizumabPhase 2Not yet recruitingMayo Clinic2026-09-28
        Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisNemolizumabPhase 3RecruitingGalderma R&D2026-08-13
        Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under NemolizumabNemolizumab—RecruitingHôpitaux Drôme Nord2026-07-28
        Nemolizumab for LSNemolizumabPhase 2Not yet recruitingUniversity of Texas Southwestern Medical Center2026-07-15
        Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic DermatitisNemolizumabPhase 2RecruitingGalderma R&D2026-06-22
        Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.NemolizumabPhase 4RecruitingThe Skin Center Dermatology Group2026-02-09

        Diseases Most Associated With It

        Open Targets association score, 0 to 1; all associations
        Atopic eczema
        0.56
        Familial primary localized cutaneous amyloidosis
        0.54
        Prurigo
        0.46
        Placental retention
        0.26
        Rheumatic disorder
        0.16
        Palindromic rheumatism
        0.16
        Intestinal disorder
        0.11
        Placenta praevia
        0.09

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630894, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q8NI17, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.